Stonegate Capital Partners Updates Coverage on Viemed Healthcare, Inc. (VMD) 4Q 2025

Dallas, Texas--(Newsfile Corp. - March 11, 2026) - Viemed Healthcare, Inc. (NASDAQ: VMD). Stonegate Capital Partners Updates Coverage on Viemed Healthcare, Inc. (NASDAQ: VMD). In FY25, Viemed grew net revenue 21% y/y to $270.3M, generated $14.9M of net income, and delivered record adj. EBITDA of $61.4M. Growth benefited from continued platform momentum and contributions from Lehan's, with additional tailwinds from the broader shift to in-home care and accelerating sleep/resupply adoption. The key headwind was short-term friction from the updated NCD, which added documentation requirements and tightened coverage criteria, temporarily moderating ventilator patient growth. We note that this did not change reimbursement levels, and vent activity has already started to normalize. Viemed ended the year with free cash flow up 141% y/y.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• Sleep and resupply are overtaking ventilation, improving recurring revenue quality and reducing regulatory sensitivity.
• Lehan's broadens commercial exposure, diversifies payors, and creates a longer runway for scaled growth.
• Despite margin mix pressure, FY26 guidance and valuation suggest durable growth remains underappreciated.

Click image above to view full announcement.

About Stonegate

Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking, equity research and capital raising for public and private companies.

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/288110

You May Also Be Interested In

• Citigroup set to join top banks in Anthropic IPO - Bloomberg
• Roots Corporation to go private in C$4.10-per-share deal with Marquee Brands
• Saba Capital funds reapprove merger plan targeting Q4 2026 close